These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32664318)

  • 1. Tumor-Associated Neutrophils Dampen Adaptive Immunity and Promote Cutaneous Squamous Cell Carcinoma Development.
    Khou S; Popa A; Luci C; Bihl F; Meghraoui-Kheddar A; Bourdely P; Salavagione E; Cosson E; Rubod A; Cazareth J; Barbry P; Mari B; Rezzonico R; Anjuère F; Braud VM
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
    Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis.
    Tang D; Zhang D; Heng Y; Zhu XK; Lin HQ; Zhou J; Tao L; Lu LM
    J Inflamm Res; 2022; 15():1079-1097. PubMed ID: 35210813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1.
    Wang X; Li Z; Sun Y
    Skin Res Technol; 2023 Jan; 29(1):e13254. PubMed ID: 36478592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
    García-Pedrero JM; Martínez-Camblor P; Diaz-Coto S; Munguia-Calzada P; Vallina-Alvarez A; Vazquez-Lopez F; Rodrigo JP; Santos-Juanes J
    J Am Acad Dermatol; 2017 Sep; 77(3):527-533. PubMed ID: 28716437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.
    Bauer C; Abdul Pari AA; Umansky V; Utikal J; Boukamp P; Augustin HG; Goerdt S; Géraud C; Felcht M
    Cancer Immunol Immunother; 2018 Jul; 67(7):1147-1157. PubMed ID: 29799076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
    Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
    Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
    Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
    Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
    Gambichler T; Gnielka M; Rüddel I; Stockfleth E; Stücker M; Schmitz L
    Cancer Immunol Immunother; 2017 Sep; 66(9):1199-1204. PubMed ID: 28501937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spleen-derived IFN-γ induces generation of PD-L1
    Langereis JD; Pickkers P; de Kleijn S; Gerretsen J; de Jonge MI; Kox M
    J Leukoc Biol; 2017 Dec; 102(6):1401-1409. PubMed ID: 28974543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis.
    Sun R; Xiong Y; Liu H; Gao C; Su L; Weng J; Yuan X; Zhang D; Feng J
    Transl Oncol; 2020 Oct; 13(10):100825. PubMed ID: 32698059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
    García-Díez I; Hernández-Ruiz E; Andrades E; Gimeno J; Ferrándiz-Pulido C; Yébenes M; García-Patos V; Pujol RM; Hernández-Muñoz I; Toll A
    Am J Dermatopathol; 2018 Sep; 40(9):647-654. PubMed ID: 29742559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
    Lopes MLDS; Gonzaga AKG; Mosconi C; Palomino GM; Mendonça EF; Batista AC; Silveira ÉJDD
    Arch Oral Biol; 2019 Feb; 98():99-107. PubMed ID: 30468994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
    He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
    J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.